Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy

Anticancer Res. 2006 Mar-Apr;26(2A):1091-5.

Abstract

Objectives: In recent years, new chemotherapy regimens with promising activity, especially in first-line therapy (induction chemotherapy) of head and neck cancer (SCCHN), have been developed. Nevertheless, a major problem concerning the response of SCCHN to chemotherapy is the high percentage of resting cells (G0-phase cells) being resistant to chemotherapy. To overcome this phenomenon, the capacity of several cytokines to switch on cells into the division cycle and progress to the chemosensitive phases (S-, M-phases) was investigated.

Materials and methods: Interleukin-6, serotonin, granulocyte colony stimulating factor (G-CSF) and epidermal growth factor (EGF) were used to stimulate G0-phase squamous cell cancer cells (Detroit 562, A431, UM-SCC 10B) for re-entry into the cell cycle to enhance the response to cisplatin. The proportion of G0-phase cells was detected through multicolor FACS analysis and Ki-67 staining.

Results: Cell cycle re-entry was most effective after combination treatment with serotonin + EGF. The proportion of G0-phase cells was significantly reduced after stimulation with serotonin + EGF (p < 0.05). Corresponding to cell cycle re-entry, the cytotoxic effect of cisplatin was significantly (p < 0.04) enhanced in the prestimulated compared to the control cells (cisplatin mono-treatment).

Conclusion: Our investigations demonstrated for the first time that sensitizing G0-phase squamous cell carcinoma cells for chemotherapy is possible by prestimulation with target cytokines. Considering that up to 95% of tumor cells are in the resting (G0) phase of the cell cycle at the initiation of chemotherapy, prestimulation with EGF and serotonin could contribute to a synchronization of cancer cells. This would clearly enhance the cytotoxic effect.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Cell Cycle / drug effects
  • Cell Cycle / physiology
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Drug Synergism
  • Epidermal Growth Factor / pharmacology
  • ErbB Receptors / metabolism
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Growth Substances / pharmacology*
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / pathology
  • Humans
  • Interleukin-6 / pharmacology
  • STAT3 Transcription Factor / metabolism
  • Serotonin / pharmacology
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Growth Substances
  • Interleukin-6
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Granulocyte Colony-Stimulating Factor
  • Serotonin
  • Epidermal Growth Factor
  • ErbB Receptors
  • Cisplatin